Tag Archives: 665 nm

ML7710 for photoactivated treatment of lung cancer

March 6, 2024 by Modulight Content
No comments
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Optimizing photosensitizer administration for cancer therapy

December 11, 2021 by Modulight Content
No comments
  Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was assessed with immunohistochemical staining and Photofrin distributions by fluorescence microscopy.       Results   Anti-tumor efficacy was similar between intratumoral and IV administration; however, smaller doses of Photofrin were Continue reading →Customer case University of Rochester belongs among the nation’s top research universities. Research at the Baran lab focuses on anti-microbial PDT and optical image processing. The aim is to develop methods for utilizing quantitative information from CT, MR and PET imaging for PDT treatment planning as well as in the search of new biomarkers and therapeutic targets. Modulight products: ML7710 (630 & 665 nm) Link to the study: Timothy M. Baran (Ph.D., PI) Laser use: Ongoing clinical Phase 1 safety & feasibility study for methylene Continue reading →

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

May 17, 2021 by Modulight Content
No comments
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →